ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Marina Biotech is exchanging 53 million of its shares, valued at $13 million dollars, for Turing Pharmaceuticals’ intranasal ketamine drug, currently in Phase III studies to treat suicidal thoughts in people with posttraumatic stress disorder. Intranasal ketamine was one of three assets acquired by Turing’s founder, Martin Shkreli, from his previous company, Retrophin. Shkreli has since been indicted for misallocating funds while at Retrophin and at a hedge fund.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter